<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18323">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01919710</url>
  </required_header>
  <id_info>
    <org_study_id>9314-rHSA/GCSF</org_study_id>
    <secondary_id>2011L01837</secondary_id>
    <nct_id>NCT01919710</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Studies of rHSA/GCSF Fusion Protein For Injection to Treat Neutropenia</brief_title>
  <official_title>Phase 1 Study of rHSA/GCSF in Neutropenia After Chemotherapy of Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin SinoBiotech Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianjin SinoBiotech Ltd.</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and efficacy studies of rHSA/GCSF fusion protein for injection in treatment of
      neutropenia induced by chemotherapy of cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A dosage climbing for the safety and efficacy studies for the neutropenia induced by
      chemotherapy cancer patients Repeat-dose studies for the safety and efficacy studied for the
      neutropenia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of participants with adverse events as a measure for safety and tolerability after single and multiple dose of rHSA/GCSF</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC after single and multiple dose of rHSA/GCSF</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Underdose (Unintentional)</condition>
  <condition>Cancer</condition>
  <condition>Tumor</condition>
  <arm_group>
    <arm_group_label>rHSA/GCSF for injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rHSA/GCSF Start from 300mcg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rHSA/GCSF</intervention_name>
    <description>for treatment of neutropenia</description>
    <arm_group_label>rHSA/GCSF for injection</arm_group_label>
    <other_name>Long acting rhG-CSF fusion protein</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - chemotherapy induced neutropenia

        Exclusion Criteria:

        - treated with other biological drugs or other neutropenia therapy drugs
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun ZHU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zailin YU, Professor</last_name>
    <phone>86-137-0101-4142</phone>
    <email>zyu88@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yan FU, PhD</last_name>
    <phone>86-10-6276-0812</phone>
    <email>yfu88@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuqin Song, MD</last_name>
      <phone>86-136-8339-8726</phone>
      <email>songyuqin622@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Ning Ding, MD</last_name>
      <phone>86-182-1104-1605</phone>
      <email>frank.dingning@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jun ZHU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuqin SONG, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 6, 2013</lastchanged_date>
  <firstreceived_date>November 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neutropenia</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>rHSA/GCSF</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
